EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dual Topoisomerase Inhibitor Is Highly Potent and Improves Antitumor Response to Radiotherapy in Cervical Carcinoma

Inken Flörkemeier iD, Hannah L Hotze, Anna Lena Heyne, Jonas Hildebrandt, Jörg P Weimer iD, Nina Hedemann, Christoph Rogmans, David Holthaus iD, Frank-André Siebert, Markus Hirt, Robert Polten, Michael Morgan und 7 weitere

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26072829 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Inken Flörkemeier und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, Kiel University and University Medical Center Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Topoisomerase Inhibitors, Radiation-Sensitizing Agents, Antineoplastic Agents. Die Arbeit nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Federal Ministry of Education and Research, Medical Faculty of Kiel University, Federal state of Schleswig-Holstein.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite advances in vaccination and early detection, the total number of cases and deaths from cervical cancer has risen steadily in recent decades, making it the fourth most common type of cancer in women worldwide. Low-income countries in particular struggle with limited resources and treatment limitations for cervical cancer. Thus, effective medicines that are simple to manufacture are needed. The newly developed dual topoisomerase inhibitor P8-D6, with its outstanding ability to induce apoptosis, could be a promising option. In this study, the efficacy of P8-D6 in combination with radiochemotherapy against cervical carcinoma was investigated in established cell lines and in a translational approach in ex vivo patient cells by measuring the cytotoxicity, cell viability and caspase activity in vitro in 2D and 3D cell cultures. Treatment with P8-D6 resulted in significantly greater cytotoxicity and apoptosis induction compared to standard therapeutic cisplatin in both 2D and 3D cell cultures. Specifically, a considerably stronger anti-proliferative effect was observed. The treatment also led to morphological changes and a loss of membrane integrity in the 3D spheroids. Radiotherapy also benefited greatly from P8-D6 treatment. In fact, P8-D6 was a more potent radiosensitizer than cisplatin. Simple synthesis, favorable physicochemical properties and high potency make P8-D6 a promising cervical cancer drug candidate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsTopoisomerase InhibitorsRadiation-Sensitizing AgentsAntineoplastic AgentsHumansFemaleApoptosisCell Line, TumorCell SurvivalCell ProliferationChemoradiotherapy

Stichwörter der Autor:innen

cervical cancerchemoradiotherapydual topoisomerase inhibitor

Substanzen

Topoisomerase InhibitorsRadiation-Sensitizing AgentsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Gynecology and Obstetrics, Kiel University and University Medical Center Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany.
  • Pharmaceutical Institute, Department of Pharmaceutical and Medicinal Chemistry, Christian-Albrecht University of Kiel, 24118 Kiel, Germany.
  • Priority Research Area Kiel Nano, Surface and Interface Sciences (KiNSIS), Kiel University, 24118 Kiel, Germany.
  • Clinic of Radiotherapy, Kiel University and University Medical Center Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany.
  • Institute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany.
  • Department of Gynecology and Obstetrics, Hannover Medical School, 30625 Hannover, Germany.

ORCID-Profile: Inken Flörkemeier, Jörg P Weimer, David Holthaus, Astrid Dempfle

Förderung

  • Federal Ministry of Education and Research
  • Medical Faculty of Kiel University
  • Federal state of Schleswig-Holstein
  • DampStiftung

Zitieren

APA

Flörkemeier, I., Hotze, H. L., Heyne, A. L., Hildebrandt, J., Weimer, J. P., Hedemann, N., Rogmans, C., Holthaus, D., Siebert, F. A., Hirt, M., Polten, R., Morgan, M., Klapdor, R., Schambach, A., Dempfle, A., Maass, N., van Mackelenbergh, M. T., Clement, B., & Bauerschlag, D. O. (2025). Dual Topoisomerase Inhibitor Is Highly Potent and Improves Antitumor Response to Radiotherapy in Cervical Carcinoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26072829

Vancouver

Flörkemeier I, Hotze HL, Heyne AL, Hildebrandt J, Weimer JP, Hedemann N, et al. Dual Topoisomerase Inhibitor Is Highly Potent and Improves Antitumor Response to Radiotherapy in Cervical Carcinoma. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26072829

BibTeX
@article{Flrkemeier2025,
  author = {Flörkemeier, Inken and Hotze, Hannah L and Heyne, Anna Lena and Hildebrandt, Jonas and Weimer, Jörg P and Hedemann, Nina and Rogmans, Christoph and Holthaus, David and Siebert, Frank-André and Hirt, Markus and Polten, Robert and Morgan, Michael and Klapdor, Rüdiger and Schambach, Axel and Dempfle, Astrid and Maass, Nicolai and van Mackelenbergh, Marion T and Clement, Bernd and Bauerschlag, Dirk O},
  title = {Dual Topoisomerase Inhibitor Is Highly Potent and Improves Antitumor Response to Radiotherapy in Cervical Carcinoma},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26072829}
}
Kostenlos starten →